Editas Medicine, Inc. (EDIT)
- Previous Close
5.22 - Open
5.25 - Bid 5.30 x 1200
- Ask 5.33 x 1200
- Day's Range
5.13 - 5.39 - 52 Week Range
5.11 - 11.91 - Volume
1,334,238 - Avg. Volume
1,915,374 - Market Cap (intraday)
437.489M - Beta (5Y Monthly) 2.02
- PE Ratio (TTM)
-- - EPS (TTM)
-2.02 - Earnings Date May 3, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.64
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
www.editasmedicine.comRecent News: EDIT
Performance Overview: EDIT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EDIT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EDIT
Valuation Measures
Market Cap
437.49M
Enterprise Value
150.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.17
Price/Book (mrq)
1.25
Enterprise Value/Revenue
1.93
Enterprise Value/EBITDA
-0.93
Financial Highlights
Profitability and Income Statement
Profit Margin
-196.12%
Return on Assets (ttm)
-20.87%
Return on Equity (ttm)
-43.17%
Revenue (ttm)
78.12M
Net Income Avi to Common (ttm)
-153.22M
Diluted EPS (ttm)
-2.02
Balance Sheet and Cash Flow
Total Cash (mrq)
323.11M
Total Debt/Equity (mrq)
10.47%
Levered Free Cash Flow (ttm)
-87.81M
Research Analysis: EDIT
Company Insights: EDIT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: EDIT
Daily – Vickers Top Buyers & Sellers for 01/05/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/08/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/05/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.